Last reviewed · How we verify
RSVpreF MDV (rsvpref-mdv)
RSVpreF MDV, developed by Pfizer Inc., is a marketed drug for preventing RSV lower respiratory tract disease in high-risk neonates. It is a monoclonal antibody, offering a novel approach to RSV prevention. The drug's key indication is a significant clinical differentiation in the market. RSVpreF MDV's commercial significance lies in its potential to reduce RSV-related hospitalizations and complications. Currently, there are no pipeline developments mentioned for this drug. As a marketed product, it has already demonstrated its efficacy and safety profile. Overall, RSVpreF MDV is a valuable addition to Pfizer's portfolio, addressing a critical unmet need in neonatal care.
At a glance
| Generic name | rsvpref-mdv |
|---|---|
| Sponsor | Pfizer Inc. |
| Drug class | Monoclonal antibody |
| Target | RSV F protein |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Approved indications
- Prevention of RSV lower respiratory tract disease in neonates at high risk of RSV disease
- Prevention of RSV lower respiratory tract disease in infants and children at high risk of RSV disease
Common side effects
Drug interactions
- Atazanavir
- CYP3A4 inhibitors
- CYP3A4 inducers
- CYP3A4 substrates
- Ritonavir
- Tipranavir
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RSVpreF MDV CI brief — competitive landscape report
- RSVpreF MDV updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI